Welcome to our dedicated page for Alpha Tau Medical Ltd. SEC filings (Ticker: DRTS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alpha Tau Medical Ltd. filings document the company's foreign-issuer current reports for Alpha DaRT clinical and regulatory updates. Recent Form 6-K reports furnish press releases and presentations covering studies in recurrent glioblastoma, recurrent cutaneous squamous cell carcinoma, pancreatic cancer, and head and neck cancer.
The filings describe trial enrollment, interim clinical data, safety observations, FDA device-related matters, conference presentations and company presentations furnished as exhibits. They also identify the company's Form 20-F reporting status and the treatment of furnished information under the Securities Exchange Act.
An insider, Levy Raphi, has filed a notice of proposed sale of 25,000 ordinary shares of the issuer through Oppenheimer & Co. Inc. on Nasdaq, with an indicated aggregate market value of 160,250.00. The filing states that 70,380,570 ordinary shares were outstanding at the time of the notice.
The securities to be sold were originally acquired as 70,000 restricted stock units (RSUs) from the issuer on 08/08/2021. Over the past three months, the same seller has already sold 20,000 ordinary shares on 01/08/2026 for gross proceeds of 121,650.00. By signing the notice, the seller represents that they are not aware of any material adverse, non‑public information about the issuer’s operations.
Form 144 for DRTS reports a planned sale of ordinary shares. The notice covers 61,745 ordinary shares to be sold through Oppenheimer & Co. Inc. on Nasdaq, with an aggregate market value of $364,295.50 and 70,380,570 shares outstanding. The shares to be sold were acquired on 02/21/2017 under an employee stock option plan from the issuer, with cash paid upon exercise.
Over the prior three months, the filer, Gat Amnon, sold additional ordinary shares of the same issuer: 16,000 shares on 11/03/2025 for $62,404.91, 33,351 shares on 12/01/2025 for $148,918.59, and 33,351 shares on 01/02/2026 for $166,120.25. The signer represents that they are not aware of any undisclosed material adverse information about the issuer’s current or prospective operations.
A holder of ordinary shares of DRTS has filed a notice of proposed sale under Rule 144. The filing states an intention to sell 20,000 ordinary shares through Oppenheimer & Co. Inc. on the Nasdaq market, with an aggregate market value of $118,000. These shares are part of 70,000 restricted stock units (RSUs) that were acquired from the issuer on 08/08/2021. The notice also reports that there were 70,380,570 shares of this class outstanding, providing a sense of the company’s total equity base.
Alpha Tau Medical Ltd. submitted a Form 6-K noting that it issued a press release titled “Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference.” The press release, dated December 18, 2025, is included as an exhibit to the report. The company clarifies that the information in this Form 6-K, including the exhibit, is being furnished rather than filed, which limits its potential liability under U.S. securities laws and controls how it may be incorporated into other regulatory documents.
Alpha Tau Medical Ltd. filed a Form 6-K to furnish a press release titled “Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update,” dated November 20, 2025. The report incorporates this press release by reference into the company’s existing Form F-3 and Form S-8 registration statements.
Alpha Tau Medical Ltd. (DRTS) furnished a Form 6-K noting it issued a press release titled “Alpha Tau Announces Receipt of Radioactive Material License at New Hampshire Manufacturing Facility.”
The submission states the information is being furnished, not deemed filed, and includes the press release as Exhibit 99.1 dated October 21, 2025.
Form 144 notice for Alpha Tau Medical Ltd. (DRTS) reports a proposed sale of 16,000 ordinary shares through Oppenheimer & Co. with an aggregate market value of $72,160. The shares represent a small fraction of the reported 70,380,570 outstanding shares (approximately 0.023%). The securities were acquired on 02/21/2017 under an employee stock options plan and the proposed approximate sale date is 10/01/2025 with payment described as cash upon exercise. The filing indicates no securities sold by the same person in the past three months. Several standard signature and date fields in the remarks section appear in the form but no specific signature, notice date, or plan-adoption date text values are provided in the content supplied.